



Beke et al. *N Eng J Med*. 2014 Jul 10;371(2):130-9

Clinical Update:

Dupilumab

- ☐ Fewer patients with skin infections associated with dupilumab (5.5%) treatment compared with placebo (24.1%)
- ☐ No infection related SAEs or eczema herpeticum in tx group
 - ☐ Placebo group, 3 patients with skin infections and 4 patients with AD exacerbations required hospitalization
- ☐ Treatment AEs: nasopharyngitis, headache, and conjunctivitis



Why allergy/ immunology?

